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A B S T R A C T
Scope: Existing research indicates that anti-inﬂammatory and antioxidant properties of berberine play
major roles in coping with oxidative stress in neurodegenerative diseases, but it is not known if this
isoquinoline alkaloid affects inﬂammatory cytokines such as interleukin 10 in focal cerebral ischemia.
Methods and results: Male Wistar rats (10 weeks old) were treated with 40 mg/kg concentration of
berberine 1 h after focal cerebral ischemia and the anti-inﬂammatory properties of berberine were
evaluated by immunohistochemical analysis, water content measure and behavioral tests. Evaluation of
infarct volume was performed by TTC staining. Immunohistochemistry and behavioral assessment
indicated recovery in treatment group compared to only ischemia group. The infarct volume decreased in
treatment group compared to ischemia group. Berberine administration signiﬁcantly decreased brain
edema and contributed to the restoration of motor function. Moreover, berberine potently contributed to
neuroprotection in motor area through downregulation of pro-inﬂammatory cytokines and upregulation
of anti-inﬂammatory cytokines.
Conclusions: These ﬁndings conﬁrm the validity of berberine as a potent anti-inﬂammatory agent in
treatment of ischemic stroke.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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Ischemic stroke is the second leading cause of death which
poses an ever-increasing challenge around the world, and is
associated with sociocultural and lifestyle changes (Feigin et al.,
2014).
Pharmacologic studies have introduced many novel therapeutic
agents that have enhanced the recovery of stroke and other
diseases (Liu et al., 2013; Jazayeri et al., 2016a, 2016b). Several
treatment options such as thrombolysis have been identiﬁed for
stroke. Adverse side effects of these approaches make themAbbreviations: TTC, 23,5-triphenyltetrazolium chloride; MCAO, middle cerebral
artery occlusion; p-AKT, phosphorylated Protein kinase B; pGSK, phosphorylated
Glycogen synthase kinase; pCREB, phosphorylated cAMP response element-binding
protein; NF-kB, nuclear factor-kB; PI3K, phosphoinositide 3-kinase; AMPK, AMP-
activated protein kinase; JAK2, Janus Kinase 2; STAT3, signal transducer and
activator of transcription 3; TNFa, tumor necrosis factor alpha; MAPK or MAP
kinase, A mitogen-activated protein kinase; PPARg, peroxisome proliferator-
activated receptor-g; MMP-9, matrix metallopeptidase 9; JNKs, c-Jun N-terminal
kinases; IL-1b, interleukin-1b; iNOS, inducible nitric oxide synthase; COX-2,
prostaglandin-endoperoxide synthase 2; IL-10, interleukin 10.
* Corresponding author. Tel.: +98 9123856305.
E-mail address: dr_nabo40@yahoo.com (N. Aboutaleb).
http://dx.doi.org/10.1016/j.jchemneu.2017.04.008
0891-0618/© 2017 The Authors. Published by Elsevier B.V. This is an open access articlimited. Therefore, new therapeutic agents or approaches are
required to increase life expectancy in patients with stroke. During
stroke and neurodegenerative diseases, different signaling path-
ways are involved in cell fate (Mehrjerdi et al., 2013; Ajami et al.,
2016; Pazoki-Toroudi et al., 2016). Targeting these signaling
pathways by therapeutic agent postpones neuronal death in the
brain after cerebral ischemia. Berberine is a yellow plant isoquino-
line alkaloid isolated from herb medicine Coptidis Rhizom,
Hydrastis canadensis, and berberis that plays an important role
in neuroprotection against pro-inﬂammatory responses and
escape from apoptotic signals (Refaat et al., 2013). A large number
of pharmacological and biological properties of berberine have
been identiﬁed including anti carcinogenic (Lu et al., 2016), anti-
inﬂammatory (Guo et al., 2016; Woo et al., 2016), anti-microbial
(Wen et al., 2016), antihypertensive (Saki et al., 2016) and
cholesterol lowering effects (Wang et al., 2014).
Existing researches have shown that berberine can ameliorate
ischemia/reperfusion injury through several mechanisms:
One, berberine can up-regulate pAkt, pGSK and pCREB, and
down-regulate NF-kB that resulted in cell survival in the acute
phase of cerebral ischemia (Zhang et al., 2012; Yu et al., 2015). Two,
it can activate Akt and PI3K p55g promoter which in turn reducesle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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et al., 2015). Three, the anti-apoptotic effect of berberine is due to
inhibition of AMPK pathway (Chen et al., 2016). Four, berberine
inhibits apoptosis through downregulation of Bax, caspase 3,
caspase 8, caspase 9 and subsequently induces autophagy in focal
cerebral ischemia (Zhang et al., 2016). Five, it activates JAK2/STAT3
signaling and inhibits endoplasmic reticulum stress (Zhao et al.,
2016). Likewise, current studies have shown anti-inﬂammatory
effects of berberine against transient global cerebral ischemia in
animal models (Singh and Chopra, 2013). Berberine may confer
neuroprotection against ischemia via modulation of potassium
currents in CA1 pyramidal neurons of hippocampus in vitro model
(Wang et al., 2004). Moreover, berberine helps to inhibit N-methyl-
D-aspartate receptor 1 immunoactivity which in turn resulting in
cell survival in CA1 hippocampus region after cerebral ischemia (Ye
et al., 2009). Herein, we evaluate the effects of berberine on
inﬂammation and inﬂammatory cytokines. Berberine might be
used as a potential therapeutic agent to reduce inﬂammation and
neuronal demise after ischemic stroke.
2. Materials and methods
2.1. Chemicals
Berberine) B3251 SIGMA) chloral hydrate (C8383 SIGMA),
paraformaldehyde (158127 SIGMA) and 2,3,5-triphenyltetrazo-
lium chloride (T8877 SIGMA(were obtained from Sigma Chemical
Co. Silicon rubber-coated monoﬁlament for MCAO model was
purchased from Doccol company (Philadelphia, PA, USA). Anti-IL10
antibody (ab34843), Anti-IL1 beta antibody (ab2105) and anti-
TNFa (ab9635) were purchased from Abcam Company (Cam-
bridge, UK). Goat anti-rabbit IgG-FITC Secondary Antibody was
obtained from Santa Cruz Biotechnology's company.
2.2. Animals and ethical statement
Ten-week-old male Wistar rats (200–250 g) were purchased
from animal laboratory of Iran University of Medical Sciences, and
all experimental tests and the procedures were conﬁrmed by theFig. 1. Berberine treatment improves neurological outcomes. (A) Post-treatment by ber
ischemia group). (B) Neurological deﬁcits were increased in ischemia group compared to
test displays recovery of treatment group compared to ischemia group (#p < 0.05 compInstitutional Animal Ethical Committee of Iran University of
Medical Sciences. Rats were maintained under standard laboratory
conditions (in a controlled temperature 25 1 C, with a 12-h dark:
12-h light cycle, 60% humidity, sterile water and food). The animals
were randomly assigned into four groups: a control group of
healthy rats (n = 20), sham-operated control group (sham, n = 20),
only ischemia + saline (MCAO, n = 20), and treatment group
(MCAO + Berberine, n = 20).
2.3. MCAO model
The animals were anesthetized with 10% chloral hydrate
(400 mg/kg body weight) by intraperitoneal injection. To make
transit focal ischemia, MCAO model was used as described
previously. In sum, a midline neck incision was made to isolate
the right common carotid artery, external carotid artery and
internal carotid artery. After occlusion of the common carotid
artery by micro-clip, external carotid artery was clamped and a
monoﬁlament nylon suture was inserted from the right common
carotid artery to the internal carotid artery by stumping external
carotid artery and gradually moved until mild resistance was felt,
conﬁrming the middle cerebral artery occlusion. After 45-min
ischemia, the monoﬁlament was removed to allow recirculation
of cerebral blood ﬂow for 24 h and the skin incision was closed by
surgical clips. During the whole surgery, body temperature of
animals were monitored and maintained at 37 C via measure-
ment by a rectal probe. The same procedure was used for sham-
operated control rats except ﬁlament insertion.
2.4. Neurobehavioral evaluation
Neurobehavioral assessments were performed 24 h after
reperfusion by an observer blinded to the treatment groups. A
six-point scale by Longa et al. was used to perform neurobehavioral
assessments (Longa et al., 1989). 0, no deﬁcits; 1, failure in fully
extending the contralateral forelimb; 2, failure to extend the
contralateral forelimb; 3, circling to the contralateral side; 4, falling
to the left; 5, no spontaneously walking and exhibition of a
depressed level of consciousness.berine signiﬁcantly decreases neurological deﬁcits score (#p < 0.01 compared with
 control and sham groups (*p < 0.001 compared to control and sham group). Ladder
ared to ischemia group).
Fig. 2. Berberine post-treatment reduced infarction volume in rats. (A) The sections were stained by immersing them in a solution of TTC and non-infarcted region appeared
red, whereas the infarcted region appeared white. (B) Berberine administration signiﬁcantly reduces total infarct volume (#p < 0.01 compared with ischemia group).
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To examine histochemical analysis, the animals were ﬁnally
anesthetized at the end of behavioral assessments and after
decapitating animals, their brains were removed. Cortex regions of
brain were dissected and maintained at –80 C prior to immuno-
histochemical analysis.
2.6. Infarct volume determination
After the behavioral assessments, the animals were re-
anesthetized and decapitated. The brains were quickly cooled in
iced saline for 10 min, and then were cut by a brain matrix to
several 2 mm thick coronal sections. The sections were incubated
in TTC at 37 C for 20 min, and then were ﬁxed in 10% buffered
formalin solution. A digital camera was used to take photograph of
the slices. Infarct volume was identiﬁed as unstained regions and
was calculated through an image analysis software.Fig. 3. Berberine post-treatment decreased brain edema. Brain water content-
signiﬁcantly increased in MCAO compared to control group (*p < 0.01). There was a
statistical difference between MCAO and MCAO + Berberine groups, conﬁrming
anti-inﬂammatory effect of Berberine (#p < 0.001 compared with MCAO group).2.7. Determination of brain water content
Brain water content was evaluated via wet/dry method in
different groups (n = 4 for each group). In summary, rats were
decapitated under an over dose mixture of ketamine and xylazine
after 24 h reperfusion. The brains were divided into ischemic and
contralateral hemispheres. Ischemic hemisphere was weighed
(wet weight) then placed in an oven at 110 C f for 24 h and again
was weighed (dry weight). Brain water content was determined via
(wet weight  dry weight)/wet weight * 100%.
2.8. Immunohistochemistry
Goat serum (10%) was used to block 5-micrometer sections
from parafﬁn embedded brain tissue. Slices were incubated with
primary antibody (1:100) (TNFa antibody, IL-1b and IL-10) at 1 mg/
ml in 1% BSA/PBS for 1 h, followed by incubation with speciﬁc
horseradish peroxidase-conjugated secondary antibody (1:150),
each for 30 min. The sections were visualized with a microscope
(Olympus, Japan). Quantiﬁcation of immunohistochemical assay
was based on ﬂuorescence intensity.
2.9. Statistical analysis
Values were expressed as means  SD. Analysis was performed
using Prism Software, version 5. Statistical difference between two
groups was determined by two-tailed Student's t tests. Comparison
of three or more groups was performed using One-way analysis of
variance followed by LSD test for post hoc analysis. Values were
considered statistically signiﬁcant in p < 0.05.
3. Results and discussion
3.1. Neurological outcomes and infarct volume
Previous studies have shown that following transient focal
cerebral ischemia oxidative stress and overexpression of pro-
inﬂammatory cytokines cause neurologic deﬁcits, brain edema and
neuronal death (Liu et al., 2015a; Yao et al., 2015; Shinohara et al.,
2016). To evaluate neuroprotective effect of berberine, we ﬁrst
examined neurobehavioral function through behavioral assess-
ment. Tianpei and coworker reported that berberine can amelio-
rate neurologic deﬁcits and infarct volume in global ischemia (Wu
et al., 1994). Our results show that there were no signiﬁcant
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in Fig. 1, signiﬁcant difference (p < 0.01) was observed between the
ischemia and treatment groups. Treatment group displayed a
signiﬁcant reduction in neurological deﬁcits score compared to
ischemia group (n = 8 for each group, p < 0.01). Likewise, the results
depicted in Fig. 1B by ladder test display following 24 h after
reperfusion; .Statistical signiﬁcant differences were observed
between control and ischemia cohorts (n = 8 for each group,
p < 0.001). Berberine administration signiﬁcantly restores motor
function than ischemia group (p < 0.05).
It has been identiﬁed that berberine can attenuate infarct
volume in MCAO animal model (Zhou et al., 2008). To examine
infarct volume, the slices were immersed in a solution of 2% TTC,
and after 20 min white areas were described as the infarcted brain
tissue and red areas were deﬁned as the non-infarcted region
(Chen et al., 2015).
As shown in Fig. 2a and b, no signiﬁcant differences between
control and ischemia group were observed by TTC staining.
Berberine post treatment reduced infarction volumes. The infarct
volume of the treatment group was 22% lower compared with
ischemia group (n = 4 for each group, p > 0.01).Fig. 4. (A) Berberine post-treatment decreased TNFa level. Immunohistochemical analy
compared with control and sham groups (*p < 0.001 compared to control and sham g
ischemia group (#p < 0.001). (B) MCAO induced a robust increase in IL-1b levels (*p < 0.0
level of IL-1b pro-inﬂammatory cytokine (#p < 0. 01 compared to MCAO group) ($p < 03.2. Brain water content
Brain edema plays an important role in the pathophysiology of
neurologic deﬁcits such as stroke and is a common sequel of post-
injury inﬂammation and blood-brain barrier (BBB) breakdown
(Manley et al., 2000). Cerebral water balance is hamper in cerebral
ischemia (Zhang et al., 2006). There is a close association between
inﬂammation and brain edema. It seems that overexpression of
interleukin-1 receptor antagonist can highly attenuate brain
edema (Masada et al., 2001). Accumulative evidences have shown
that berberine can contribute to normalization of cerebral water
balance after brain injury via inhibition of Glia-mediated
inﬂammation (Chen et al., 2014). To evaluate the anti-inﬂamma-
tory effects of berberine, we measured brain water content in
different groups. Following 24 h reperfusion, water content of the
brain tissue for the control, sham, ischemia and treatment groups
were77.35%, 78.83%, 80.63%, 77.89% respectively. Our results
indicated a signiﬁcant difference between sham and ischemia
groups (p < 0.01).
Water content of the brain increased signiﬁcantly in ischemia
group compared to control and sham group. Decreased watersis results demonstrated that MCAO markedly increased the protein levels of TNFa
roups). TNFa proinﬂammatory cytokine was signiﬁcantly decreased compared to
01 compared to control and sham groups). Berberine post-treatment decreased the
. 01 compared to control and sham groups).
Fig. 5. Following MCAO, IL-10 level was increased compared to control and sham groups. A robust increase in IL-10 anti-inﬂamatory cytokine was observed after treatment by
berberine in cortex region (#p < 0.05 compared with MCAO group) (*p < 0.001 compared to control and sham groups).
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clear evidence that berberine alleviates brain edema formation
following ischemic stroke (Fig. 3).
3.3. Immunohistochemical analysis
Exiting researches have shown that berberine can contribute to
neuroprotection in coping with oxidative stress and ischemic
stroke through targeting different signaling pathways (Zhang et al.,
2012). In addition, this isoquinoline alkaloid can interact with
mRNAs that lead to up-regulation of several proteins and escape of
proapoptic signals (Chai et al., 2014). Berberine can inhibit
proinﬂammatory responses via AMPK activation in macrophages
(Jeong et al., 2009). Recent studies have shown that berberine
might downregulate proinﬂammatory cytokines in a AMPK-
independent manner (Woo et al., 2016). Likewise, Berberine can
suppress proinﬂammatory responses through downregulation of
proinﬂammatory cytokines such as TNFa and IL-6 in AcLDL-
stimulated macrophages via PPARg signaling pathway (Chen et al.,
2008; Spatuzza et al., 2014). Moreover, Berberine may decrease
inﬂammation by targeting MAPK pathway that in turn suppresses
the expression of proinﬂammatory cytokines (Li et al., 2014).
Berberine inhibits cell invasion by supressing TNF-a-induced
MMP-9 in human breast cancer (Kim et al., 2008).
In present work, immunohistochemical studies have shown
that TNFa expression was signtiﬁcantly increased than control and
sham groups (p < 0.001). Berberine highly inhibited the expression
of TNFa compared to MCAO cohorts (Fig. 4A). Our results displayed
berberine administration exhibited a signiﬁcant anti-inﬂammato-
ry effect on cerebral ischemia through supression of proinﬂam-
matory cytokines.
It has been recognized that berberine can decrease inﬂamma-
tory agents-induced interleukin-1b and TNFa ensuing inﬂamma-
tion in human lung cells (Lee et al., 2007). Many emerging
evidences have shown that berberine contributes to cell survival
and inhibition of inﬂammation by downregulating IL-1b expres-
sion (Liu et al., 2015b, 2016). For example, berberine mediates
inhibition of cartilage degeneration in IL-1b-stimulated rat
chondrocytes through downregulation of IL-1b in a Akt-depen-
dent fasion (Zhao et al., 2014). Besides, following deactivation of
JNK signaling pathways by berberine, lower levels of TNF-a and IL-1b have been observed in acute pancreatitis disease (Choi et al.,
2016).
Likewise, in present work our ﬁnding indicates that IL-1b level
signtiﬁcantly was increased in MCAO group than control animals
(2200pikel/um2), indicating a potent detrimental effect of this
proinﬂammatory cytokine in cerebral ischemia. Decreased level of
IL-1b was found in treatment group (p < 0.05).
On the other hand, berberine can increase the expression of
anti-inﬂammatory cytokines. In work by Kim and coworker
berberine not only decreases the expression of iNOS, COX-2, IL-
1b, IL-6, and TNF-a, but also enhances IL-10 expression to inhibit
lipid peroxidation in inﬂammatory bowel diseases (Lee et al.,
2010). We examined the effects of berberine on anti-inﬂammatory
cytokines.
We found that focal cerebral ischemia increased IL-10 expres-
sion (200pikel/um) compared to control animals (less of 100 pikel/
um), whereas berberine dramatically elevated IL-10 levels more
than both control and ischemia groups (270 pikel/um), again
conﬁrming potent anti-inﬂammatory effects of berberine (Fig. 5).
4. Conclusion
In conclusion, our ﬁndings indicate the potent anti-inﬂamatory
effects of berberine on MCAO model in Wistar rats. Our results
show that berberine ameliorates infarct volume, brain edema
formation, and contributes to recovery of motor function after
focal cerebral ischemia via downregulation of pro-inﬂammatory
cytokines and upregulation of anti-inﬂammatory cytokines.
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